Value-based pricing — an opportunity to incentivise effective prescribing

摘要

At the end of 2010, the Department of Health published the consultation on its policy to change the way the NHS pays for new medicines (PJ, 1/8 January 2011, p2). By 2014, a new system of "value-based pricing" (VBP) will replace the current Pharmaceutical Price Regulation Scheme (PPRS), which is a voluntary agreement between the DoH and the pharmaceutical industry, whereby companies negotiate profit rates from drug sales to the NHS every five years based on price and profit controls.